for reproxalap for the treatment of dry eye disease. Reproxalap is a first-in-class small-molecule modulator of reactive aldehyde species (RASP), which are generally elevated in ocular and ...

In patients with dry eye disease, small-molecule RASP (reactive aldehyde species) may contribute to ocular inflammation, diminished tear production, ocular redness, and changes in tear lipid ...

The Massachusetts-based biotech said a meeting with the FDA to discuss the programme has given it the confidence to press ahead with filing for approval of the RASP ... of dry eye disease ...

Aldeyra Therapeutics' stock rebounds 70%, offering a contrarian opportunity with Reproxalap targeting a $216M market. Learn ...

Our late-stage product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal ...

Per draft FDA dry eye disease guidance, to be considered for regulatory approval in the United States, efficacy in dry eye disease may be demonstrated with two symptom trials and two sign trials.